Comparison of receptor-mediated endocytosis kinetics between wild-type t-PA and recombinant pamiteplase in isolated rat hepatocytes and liver cell plasma membranes

References

• BAKHIT, C., LEWIS, D., BILLINGS, R. and MALFROY, B., 1987, Cellular catabolism of recombinant tissue-type plasminogen activator. Journal of Biological Chemistry, 262, 8716–8720.
   PubMedGoogle Scholar
• BAUR, H. and POND, S. M., 1975, Criteria of viability of isolated liver cells. Hoppe-Seyler's Zeitschrift fur Physiologische Chemie, 356, 827–838.
   PubMedGoogle Scholar
• CAMANI, C. and KRUITHOF, K. O., 1994, Clearance receptors for tissue-type plasminogen activator. International Journal of Hematology, 60, 97–109.
   PubMedGoogle Scholar
• EINARSSON, M., SMEDSROD, B. and PERTOFT, H., 1988, Uptake and degradation of tissue plasminogen activator in rat liver. Thrombosis and Haemostasis, 59, 474–479.
   PubMedGoogle Scholar
• IIDA, S., IwAmoTo, M., Suzum, M. and KOMATSU, T., 1988, Metabolic fate of recombinant human tissue plasminogen activator (rt-PA) (1). Xenobiotk Metabolism and Disposition, 3, 309–329.
   Google Scholar
• KANEMOTO, N., OOTO, Y. and HIROSAWA, K., 1991, Intravenous recombinant tissue-type plasminogen activator (rt-PA) and urokinase (UK) in patients with evolving myocardial infarction. A multicenter double-blind, randomised trial in Japan. Japanese Circulation Journal, 55,250–261.
   PubMedGoogle Scholar
• KATO, M., KAMIYAMA, H., OKAZAKI, A., KATO, Y. and SUGIYAMA, Y., 1997, Mechanism for the non-linear pharmacokinetics of erythropoietin in rats. Journal of Pharmacology and Experimental Therapeutics, 283, 520–527.
   PubMedGoogle Scholar
• KATOH, M., SUZUKI, Y., MIYAMOTO, I. and WATANABE, T., 1991, Biochemical and pharmacokinetics properties of pamiteplase, a novel fibrinolytic agent. Thrombosis and Haemostasis, 65, 1193.
   Google Scholar
• KAWASAKI, T., KAWAMURA, S., KATOH, S. and TAKENAKA, T., 1993a, Experimental model of carotid artery thrombosis in rats and the thrombolytic activity of Y1V1866, a novel modified tissue-type plasminogen activator. Japanese Journal Pharmacology, 63, 135–142.
   PubMedGoogle Scholar
• KAWASAKI, T., KATOH, M., KAKU, S., GUSHIMA, H., TAKENAKA, T, Yu', Y. and KAWAI C., 1993b, Thrombolytic activity of a novel modified tissue-type plasminogen activator, YM866, in a canine model of coronary artery thrombosis. Japanese Journal Pharmacology, 63, 9–16.
   Google Scholar
• KAWASAKI, T., KATOH, M., KAKU, S., GUSHIMA, H., TAKENAKA, T., Yu', Y. and KAWAI C., 1993c, Thrombolysis with intracoronary administration of Y1V1866, a novel modified tissue-type plasminogen activator, in a canine model of coronary artery thrombosis. Japanese Journal Pharmacology, 63, 319–325.
   Google Scholar
• KAWAUCHI, Y., MORINAGA, T., YOKOTA, M., KINOSHITA, A., KAWAMURA, K., SUZUKI, Y., TAKAYAMA, M., FURUICHI, K. and GUSHIMA, H., 1991, Gene construction and large scale production of a novel fibrinolytic agent(pamiteplase) in CHO cells. Thrombosis and Haemostasis, 65, 1193.
   Google Scholar
• KRAUSE, J., SEYDEL, W., HEINZEL, G. and TANSEWELL, P., 1990, Different receptors mediate the hepatic catabolism of tissue-type plasminogen activator and urokinase. Biochemical Journal, 267, 647–652.
   PubMedGoogle Scholar
• KUWABARA, T., KATO, Y., KoBAYASHI, S., SUZUKI, H. and SUGIYAMA, Y., 1994, Non-linear pharmacokinetics of a recombinant human granulocyte colony-stimulation factor derivative (Nartograstim): species differences among rats, monkey and humans. Journal of Pharmacology and Experimental Therapeutics, 271, 1535–1543.
   PubMed Web of Science ®Google Scholar
• NGUYEN, G., SELF, S. J. and KRUITHOF, E. K. O., 1992, Demonstration of a specific clearance for tissue-type plasminogen activator on rat Novikoff hepatoma cells. Journal of Biological Chemistry, 267, 6249–6256.
   PubMedGoogle Scholar
• OIKAWA, K., KAMIMURA, H., WATANABE, T., HIGUCHI, S. and MIYAMOTO I., 1996a, Pharmacokinetics of Y1V1866 and t-PA after intravenous administration to rats and dogs. Clinical Pharmacology and Therapy, 6, 2391–2396.
   Google Scholar
• OIKAWA, K., KAMIMURA, H., WATANABE, T., MIYAMOTO, I. and HIGUCHI, S., 1996b, Metabolic fate of Y1V1866, a novel fibrinolytic agent. Xenobiotic Metabolism and Disposition, 11, 1–10.
   Google Scholar
• OWENSBY, D. A., SOBEL, B. E. and SCHWARTZ, A. L., 1988, Receptor-mediated endocytosis of tissue-type plasminogen activator by the human hepatoma cell line Hep G2. Journal of Biological Chemistry, 263, 10587–10594.
   PubMedGoogle Scholar
• PARDRIDGE, W. M., HERLE, A. J. V., NARUSE, R. T. and COSTIN, A., 1983, In vivo quantification of receptor-mediated uptake of asialoglycoproteins by rat liver. Journal of Biological Chemistry, 258, 990–994.
   Google Scholar
• SUGIYAMA, Y. and HANANO, M., 1989, Receptor-mediated transport of polypeptide hormones and its importance in the overall hormone disposition in the body. Pharmaceutical Research, 6, 192-2 02.
   Google Scholar
• STANG, E., KRAUSE, J., SEYDEL, W., BERG, T. and Roos, N., 1992, Endocytosis and intracellular processing of tissue-type plasminogen activator by rat liver cells in vivo. Biochemical Journal, 282, 841–851.
   PubMedGoogle Scholar
• TANS WELL, P., HEINZEL, G., GREISCHEL, A. and KRAUSE, J., 1990, Non-linear pharmacokinetics of tissue-type plasminogen activator in three animal species and isolated perfused rat liver. Journal of Pharmacology and Experimental Therapeutics, 255, 318–323.
   PubMedGoogle Scholar
• VERSTRAETE, M. and COLLEN, D., 1985, Randomized trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Lancet, i, 842–847.
   Google Scholar
• YANAI, S., SUGIYAMA, Y., KIM, D. C., IcA, T., FUWA, T. and HANANO, M., 1991, Kinetic analysis of receptor-mediated endocytosis of epidermal growth factor by isolated rat hepatocyte. American Journal of Physiology, 260, C457–467.
   PubMed Web of Science ®Google Scholar